Unknown

Dataset Information

Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability.


ABSTRACT: Enhancements in clinical-grade next-generation sequencing (NGS) have fueled the advancement of precision medicine in the clinical oncology field. Here, we survey the molecular profiles of 1,113 patients with diverse malignancies who successfully underwent clinical-grade NGS (236-404 genes) in an academic tertiary cancer center. Among the individual tumors examined, the majority showed at least one detectable alteration (97.2%). Among 2,045 molecular aberrations was the involvement of 302 distinct genes. The most commonly altered genes were TP53 (47.0%), CDKN2A (18.0%), TERT (17.0%), and KRAS (16.0%), and the majority of patients had tumors that harbored multiple alterations. Tumors displayed a median of four alterations (range, 0-29). Most individuals had at lea

SUBMITTER: Bieg-Bourne CC 

PROVIDER: S-EPMC5690871 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature